Clinical trials: Geriatric Population
- Condition Geriatric Population
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
- Trial name
- RESULT (NCT06500702)
- Testing
- frexalimab, brivekimig, rilzabrutinib
- Where
- 79 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
- Trial name
- NCT00735371
- Testing
- LDX 30 mg, LDX 50 mg, LDX 70 mg
- Where
- 45 sites in United States
- Volunteers
- 314 people
- Sponsor
- Shire
Asthma
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to…
- Trial name
- NCT03387241
- Testing
- Fluticasone/ Formoterol, fluticasone/ salmeterol
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Latent Tuberculosis Infection
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients.
- Trial name
- NCT05746611
- Testing
- Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected
- Where
- China
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Pneumococcal Infectious Disease
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years…
- Trial name
- NCT07071701
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Influenza vaccine
- Where
- China
- Volunteers
- 19,267 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Asthma
Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
Prospective, parallel-group, randomized study to evaluate the compliance to the treatment of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the association Fluticasone 250 mcg/dose…
- Trial name
- ADERE (Ped) (NCT01476059)
- Testing
- Telephone follow-up, No telephone follow-up
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Malaria, Vivax
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.
- Trial name
- NCT06666491
- Testing
- Tafenoquine, Primaquine, Chloroquine
- Where
- 5 sites in India
- Volunteers
- 324 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
Study to evaluate the efficacy of VX-661 in combination with ivacaftor (IVA, VX-770) through Week 12 in participants with cystic fibrosis (CF) who are heterozygous for the F508del mutation on the CF transmembrane conductance…
- Trial name
- NCT02516410
- Testing
- VX-661 plus ivacaftor combination, Ivacaftor
- Where
- 41 sites in United States, Australia and 5 more
- Volunteers
- 168 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Asthma
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding dose of CHF 1535 via HFA-134a…
- Trial name
- NCT00862394
- Testing
- BDP/Formoterol Next DPI, Foster
- Where
- Germany
- Volunteers
- 783 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Persistent Allergic Rhinitis
A Study to Evaluate DEP114 for the Treatment of Acute Exacerbation of Persistent Allergic Rhinitis in Children Aged 6 to Under 12 Years
The goal of this clinical trial is to learn whether DEP114 is effective in treating acute exacerbations of persistent allergic rhinitis in children aged 6 to less than 12 years. The study will also evaluate the safety of DEP114.
- Trial name
- DESPRIN (NCT07835074)
- Testing
- DEP114, Desloratadine
- Volunteers
- 316 people
- Sponsor
- EMS
Acute Respiratory Infection
Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI
The purpose of this study is is to demonstrate superiority of Polyoxidonium, nasal and sublingual spray, 6 mg/ml over placebo in children aged from 1 to 12 years with acute respiratory viral infections.
- Trial name
- NCT03840135
- Testing
- Polyoxidonium 6 mg/ml
- Where
- 11 sites in Russia
- Volunteers
- 172 people
- Sponsor
- NPO Petrovax
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- STRIVE (NCT00909532)
- Testing
- Ivacaftor
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Seasonal Influenza
Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated
This study is a randomized, double-blind phase Ⅳ clinical trial of quadrivalent influenza vaccine (Split Virion), inactivated manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the lot-to-lot…
- Trial name
- NCT05512494
- Testing
- Quadrivalent Influenza Vaccine (Split Virion), inactivated
- Where
- China
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19, SARS-CoV-2 Infection
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
The objective of study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E as booster compared with Sinopharm inactivated COVID-19 vaccine as booster.
- Trial name
- NCT05239806
- Testing
- SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged…
- Trial name
- COVID-19 (NCT04863638)
- Testing
- 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Influenza, Influenza A
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the…
- Conditions
- Influenza, Influenza A, Influenza, Human, Influenza Type B
- Trial name
- NCT06385821
- Testing
- Grippol Quadrivalent, Grippol Plus
- Where
- 14 sites in Russia
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Chemotherapy Induced Nausea and Vomiting
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
- Trial name
- NCT01596413
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Meningococcal Meningitis
Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine
This trial adopts an open-label design combined with randomized, blinded, placebo-controlled and active-controlled design. The purpose of this trial is to evaluate the safety and immunogenicity of a Group ACYW135X Meningococcal…
- Trial name
- NCT07374510
- Testing
- high-dose Group ACYW135X Meningococcal Conjugate Vaccine, medium-dose Group ACYW135X Meningococcal Conjugate Vaccine, low-dose Group ACYW135X Meningococcal Conjugate Vaccine
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Acute Respiratory Viral Infection
Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old
The multicenter double-blind placebo-controlled randomized in parallel-group. The objective of this study is to evaluate efficacy and safety of Raphamin in the treatment of acute respiratory viral infection (ARVI) in children…
- Trial name
- NCT04918771
- Testing
- Raphamin
- Where
- 29 sites in Russia
- Volunteers
- 435 people
- Sponsor
- Materia Medica Holding
Haemophilus Influenzae Type B Infection
Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
This trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the…
- Trial name
- NCT06621654
- Testing
- Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine, Haemophilus Influenzae Type b Conjugate Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.